We are live on
!
Find out more
SCM
Superstring Capital Management Portfolio holdings
AUM
$158M
1-Year Est. Return
418.32%
This Fund
S&P 500
This Quarter
Est. Return
+40.72%
1 Year Est. Return
+418.32%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$158M
AUM Growth
+$18.4M
(+13%)
Cap. Flow
-$14.8M
Cap. Flow
% of AUM
-9.34%
Top 10 Holdings %
Top 10 Hldgs %
63.75%
Holding
43
New
8
Increased
13
Reduced
9
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axsome Therapeutics
AXSM
|
+$9.26M |
| 2 |
Revolution Medicines
RVMD
|
+$7.46M |
| 3 |
Genmab
GMAB
|
+$6.22M |
| 4 |
Cogent Biosciences
COGT
|
+$4.13M |
| 5 |
Trevi Therapeutics
TRVI
|
+$3.97M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Summit Therapeutics
SMMT
|
+$16.9M |
| 2 |
UroGen Pharma
URGN
|
+$5.31M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$4.92M |
| 4 |
Immunovant
IMVT
|
+$4.55M |
| 5 |
IQVIA
IQV
|
+$4.38M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Roivant Sciences
ROIV
$25.2B
| $907K | 0.57% |
+25,623
| New | +$757K |
|
27
Tonix Pharmaceuticals
TNXP
$225M
| $812K | 0.51% |
63,648
+108
| +0.2% | +$1.39K |
|
28
Protara Therapeutics
TARA
$233M
| $464K | 0.29% |
121,457
| – | – |
|
|
FTH
29
Faeth Therapeutics
FTH
$1.03B
| $354K | 0.22% |
+14,175
| New | +$328K |
|
|
BOLD
30
Boundless Bio
BOLD
$65.3M
| $138K | 0.09% |
+55,356
| New | +$85.2K |
|
31
Biomea Fusion
BMEA
$147M
| $85.3K | 0.05% |
250,000
| – | – |
|
|
YARW
32
Yarrow Bioscience
YARW
$80.7M
| $39.9K | 0.03% |
+1,225
| New | +$39.7K |
|
33
Arvinas
ARVN
$614M
| – | – |
-312,620
| Closed | -$3.31M |
|
34
Cullinan Oncology
CGEM
$1.42B
| – | – |
-59,484
| Closed | -$845K |
|
35
Century Therapeutics
IPSC
$382M
| – | – |
-119,308
| Closed | -$270K |
|
|
36
IQVIA
IQV
$44.1B
| – | – |
-25,668
| Closed | -$4.38M |
|
37
Pfizer
PFE
$162B
| – | – |
-74,000
| Closed | -$2.08M |
|
|
PTN
38
Palatin Technologies
PTN
$22.6M
| – | – |
-35,969
| Closed | -$627K |
|
|
39
Summit Therapeutics
SMMT
$14B
| – | – |
-892,873
| Closed | -$16.9M |
|
40
Taysha Gene Therapies
TSHA
$1.82B
| – | – |
-258,269
| Closed | -$1.15M |
|
41
Travere Therapeutics
TVTX
$6.15B
| – | – |
-102,754
| Closed | -$3.05M |
|
|
42
Vertex Pharmaceuticals
VRTX
$138B
| – | – |
-11,010
| Closed | -$4.92M |
|
|
ORKA
43
Oruka Therapeutics
ORKA
$6.13B
| – | – |
-63,591
| Closed | -$3.12M |
|
Similar funds
FCM
SF
CCA
VFIA
BTC
SWM
AWA
MA
Superstring Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Superstring Capital Management held 43 positions worth $158M, up 13% from $140M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Superstring Capital Management withdrew a net $14.8M in Q2 2026, closing 11 positions and reducing 9 holdings. Its most notable exit was Summit Therapeutics, an estimated $16.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Superstring Capital Management opened a new position in Revolution Medicines worth $9.56M.
- Superstring Capital Management's largest Q2 2026 buy was Revolution Medicines: 51,053 shares worth $9.56M.
- Superstring Capital Management added most to Axsome Therapeutics in Q2 2026, an estimated $9.26M increase.
- Superstring Capital Management's biggest Q2 2026 reduction was UroGen Pharma, cutting an estimated $5.31M.
- Superstring Capital Management fully exited Summit Therapeutics in Q2 2026, selling an estimated $16.9M.
- Superstring Capital Management's ten largest holdings make up 64% of its $158M portfolio in Q2 2026.
- Superstring Capital Management opened 8 new positions and closed 11 in Q2 2026.
- Superstring Capital Management's portfolio value rose 13% quarter-over-quarter to $158M.
Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.